Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC202 Plus Limertinib Versus Osimertinib in First-Line EGFRm+/MET+ Advanced NSCLC
NCT07897188Phase 3Not yet recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 3 trial of askc202, limertinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
askc202limertinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07897188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897188.